Skip to main content

Table 2 Basic characteristics

From: A heart failure phenotype stratified model for predicting 1-year mortality in patients admitted with acute heart failure: results from an individual participant data meta-analysis of four prospective European cohorts

  BIOSTAT-index (n = 1469) BIOSTAT-validation (n = 809) TRIUMPH (n = 372) COACH (n = 927) Overall (n = 3577)
Characteristics
 Female sex 407 (27.7%) 309 (38.2%) 135 (36.3%) 344 (37.1%) 1195 (33.4%)
 Age, mean (SD), years 68.1 (12.4) 74.7 (10.8) 70.7 (12.3) 70.5 (11.4) 70.5 (12.0)
 BMI, mean (SD) 27.8 (5.61) 28.6 (6.63) 28.3 (5.54) 26.2 (5.15) 27.6 (5.80)
 Blood pressure, mean (SD), mmHg
  Systolic 124 (22.0) 122 (22.3) 131 (28.8) 118 (21.0) 122 (22.9)
  Diastolic 73.9 (13.3) 66.5 (13.5) 76.2 (17.3) 68.5 (12.1) 71.1(14.0)
 Heart rate, mean (SD) 82.5 (20.5) 77.0 (17.5) 88.1 (22.3) 74.4 (13.4) 79.7 (18.9)
 Previous HF hospitalization 419 (28.5%) 234 (28.9%) 80 (21.5%) 293 (31.6%) 1026 (28.7%)
 NYHA class
  I/II 424 (28.9%) 201 (24.8%) 67 (18.0%) 49 (5.3%) 741 (20.7%)
  III 756 (51.5%) 407 (50.3%) 193 (51.9%) 477 (51.5%) 1833 (51.2%)
  IV 249 (17.0%) 201 (24.8%) 93 (25.0%) 393 (42.4%) 936 (26.2%)
 HF subtypes
  HFrEF 1159 (78.9%) 332 (41.0%) 254 (68.3%) 623 (67.2%) 2368 (66.2%)
  HFmrEF 187 (12.7%) 201 (24.8%) 54 (14.5%) 146 (15.7%) 588 (16.4%)
  HFpEF 123 (8.4%) 276 (34.1%) 64 (17.2%) 158 (17.0%) 621 (17.4%)
Medical history
 Myocardial infarction 513 (34.9%) 409 (50.6%) 141 (37.9%) 387 (41.7%) 1450 (40.5%)
 CABG 244 (16.6%) 133 (16.4%) 103 (27.7%) 149 (16.1%) 629 (17.6%)
 Atrial fibrillation 681 (46.4%) 372 (46.0%) 153 (41.1%) 410 (44.2%) 1616 (45.2%)
 ICD/pacemaker 336 (22.9%) 83 (10.3%) 111 (29.8%) 79 (8.5%) 609 (17.0%)
 COPD 264 (18.0%) 184 (22.7%) 68 (18.3%) 237 (25.6%) 753 (21.1%)
 Peripheral arterial disease 173 (11.8%) 161 (19.9%) 81 (21.8%) 155 (16.7%) 570 (15.9%)
 Stroke 136 (9.3%) 176 (21.8%) 67 (18.0%) 144 (15.5%) 523 (14.6%)
 Diabetes 505 (34.4%) 281 (34.7%) 132 (35.5%) 254 (27.4%) 1172 (32.8%)
Medication*
 β-Blocker use 1164 (79.2%) 562 (69.5%) 231 (62.1%) 427 (46.1%) 2384 (66.6%)
 ACE/ARBs use 1007 (68.6%) 504 (62.3%) 231 (62.1%) 463 (49.9%) 2205 (61.6%)
 Diuretics use 1467 (99.9%) 800 (98.9%) 261 (70.2%) 692 (74.6%) 3220 (90.0%)
Laboratory, mean (SD)
 Hemoglobin, mmol/L 8.14 (1.20) 7.92 (1.30) 8.17 (1.30) 8.39 (1.22) 8.16 (1.25)
 Hematocrit, % 39.8 (5.41) 39.9 (6.20) 40.0 (6.06) 41.0 (5.81) 40.1 (5.79)
 Serum potassium, mmol/L 4.21 (0.58) 4.18 (0.50) 4.24 (0.64) 4.21 (0.61) 4.21 (0.58)
 Serum sodium, mmol/L 139 (4.07) 138 (3.63) 139 (4.12) 138 (4.66) 139 (4.15)
 Serum creatinine, μmol/L 115 (52.3) 111 (51.7) 126 (63.7) 123 (54.0) 117 (54.1)
 BUN, mmol/L 16.4 (13.1) 10.6 (6.20) 12.0 (9.76) 10.7 (5.64) 13.0 (10.1)
 NT-proBNP, ng/L 7670 (8830) 4990 (8080) 6910 (7650) 4960 (6980) 6080 (8120)
Death
 HFrEF 195 (16.8%) 94 (28.3%) 54 (21.3%) 126 (20.2%) 469 (19.8%)
 HFmrEF 40 (21.4%) 42 (20.9%) 11 (20.4%) 28 (19.2%) 121 (20.6%)
 HFpEF 26 (21.1%) 69 (25.0%) 11 (17.2%) 22 (13.9%) 128 (20.6%)
  1. *Medication use was assessed prior to hospital admission
  2. Number (%) of death within 1 year of follow-up by study cohort and HF phenotype